Charlottesville, Virginia – KeViRx, Inc. (“KeViRx”) has been selected to join Blue Knight, a joint initiative between Johnson & Johnson Innovation – JLABS and the Biomedical Advanced Research and Development Authority (BARDA), a component of the U.S. Department of Health and Human Services.  Blue Knight is a collaborative program designed to anticipate and respond to …

Richmond, VA, (Richmond Times Dispatch) – While many of us have been focused this month on the Olympics and Super Bowl, another competition is underway that could make an enormous impact on our community and nation. The Build Back Better Regional Challenge is a historic grant competition issued by the U.S. Economic Development Administration. BBBRC …

McLean, Va. – The Center for Excellence in Education (CEE) announces its spring 2022 schedule of virtual science, technology, engineering, and mathematics (STEM) Lyceums events for high school students. CEE’s STEM Lyceums are free monthly virtual meetings that will engage high school students in discussion and exploration of STEM concepts and unique STEM career pathways, provided …

Washington, D.C., Children’s National Hospital successfully performed the first-ever high-intensity focused ultrasound (HIFU) surgery on a pediatric patient with neurofibromatosis (NF). This is the youngest patient to undergo HIFU treatment in the world. The advancement of children’s medical devices in the U.S. continues to significantly lag behind adult devices. This is why this milestone marks …

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called Lacripep, today announced that in late 2021 it received official minutes from a Type C meeting with the U.S. Food and Drug Administration (FDA) regarding the development of Lacripep …

CHARLOTTESVILLE, Va., (GLOBE NEWSWIRE) — Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of …